18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG.
This article reviews possible use of (18)F-labelled radiopharmaceuticals in oncology with positron emission tomography. The characteristics of various (18)F-labelled compounds are proteins and peptides, those that bind to. receptors, agents to assess hypoxia, and agents to evaluate gene therapy are highlighted. Furthermore, different (18)F-labelled tissue specific agents are indicated for the detection and monitoring of various malignancies: melanoma, brain tumours, breast cancer, prostate cancer and colorectal cancer. (18)F-fluorodeoxyglucose has been excluded from this summary.
Varagnolo
L
L
Division of Nuclear Medicine, Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.
Stokkel
M P
MP
Mazzi
U
U
Pauwels
E K
EK
D000818:Animals; D005462:Fluorine Radioisotopes; D006801:Humans; D007553:Isotope Labeling; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000379:methods*
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals